Compare BioNTech SE - ADR (BNTX) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs FuelCell Energy Inc — how do they compare? BioNTech SE - ADR trades at $93.16 (market cap $23.31B), while FuelCell Energy Inc trades at $21.29 (market cap $1.54B). The key difference: BioNTech SE - ADR is far larger — about 15.1× FuelCell Energy Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | FCEL | |
|---|---|---|
Market Cap | $23.31B | $1.54B |
Sector | Health | Industrials |
52-Week High | $119.34 | $36.01 |
52-Week Low | $83.89 | $3.92 |
Enterprise Value | $6.60B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
FCEL trades at $21.32, up 7.51% in the last 24 hours, with a bearish technical signal and RSI near oversold levels. The company reported a net loss of $187.9 million in 2025, with negative gross and net income margins, though revenue grew to $158.16 million. Recent news highlights partnerships with Siemens and focus on AI-driven power demand, but cash flow from operations remains negative.
The outlook is mixed: analyst consensus is split between Buy and Hold with a $20.75 price target, slightly below current price. Key risks include persistent losses, high cash burn, and competitive pressures in the hydrogen sector. Upside potential hinges on execution of growth initiatives and profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
